Matthew L Sherman insider trades: Deciphera Pharmaceuticals (DCPH) stock sales
Trades on the price chart
Daily close, with an arrow on each day they bought or sold
Companies
Where Matthew reports to the SEC
Open-market buys and sales
74 trades reported on SEC Form 4, newest first
| Date | Stock | Type | Shares | Price | Value | Holding | Reported |
|---|---|---|---|---|---|---|---|
| Feb 16, 2024 | DCPH | ↓ Sell | 2,615 | $15.62 | $41K | Direct | Feb 20, 2024 (4d) |
| Jan 16, 2024 | DCPH | ↓ Sell | 2,435 | $14.47 | $35K | Direct | Jan 18, 2024 (2d) |
| Dec 13, 2023 | DCPH | ↓ Sell | 2,792 | $15.37 | $43K | Direct | Dec 14, 2023 (1d) |
| Oct 30, 2023 | DCPH | ↓ Sell | 2,360 | $12.02 | $28K | Direct | Oct 31, 2023 (1d) |
| Oct 2, 2023 | DCPH | ↓ Sell | 2,942 | $12.68 | $37K | Direct | Oct 4, 2023 (2d) |
| Jun 16, 2023 | DCPH | ↓ Sell | 1,655 | $14.40 | $24K | Direct | Jun 21, 2023 (5d) |
| Feb 16, 2023 | DCPH | ↓ Sell | 971 | $15.10 | $15K | Direct | Feb 17, 2023 (1d) |
| Jan 17, 2023 | DCPH | ↓ Sell | 2,403 | $21.24 | $51K | Direct | Jan 19, 2023 (2d) |
| Oct 3, 2022 | DCPH | ↓ Sell | 2,587 | $18.73 | $48K | Direct | Oct 5, 2022 (2d) |
| Jun 16, 2022 | DCPH | ↓ Sell | 1,768 | $10.75 | $19K | Direct | Jun 21, 2022 (5d) |
| Feb 16, 2022 | DCPH | ↓ Sell | 984 | $9.05 | $9K | Direct | Feb 18, 2022 (2d) |
| Oct 4, 2021 | DCPH | ↓ Sell | 2,659 | $33.17 | $88K | Direct | Oct 6, 2021 (2d) |
| Feb 16, 2021 | DCPH | ↓ Sell | 132 | $48.87 | $6K | Direct | Feb 18, 2021 (2d) |
| Apr 3, 2018 | XLRN | ↓ Sell | 4,600 | $38.43 | $177K | Direct | Apr 4, 2018 (1d) |
| Jan 3, 2018 | XLRN | ↓ Sell | 4,633 | $42.71 | $198K | Direct | Jan 4, 2018 (1d) |
| Sep 12, 2017 | XLRN | ↓ Sell | 18,400 | $38.41 | $707K | Direct | Sep 14, 2017 (2d) |
| Jul 5, 2017 | XLRN | ↓ Sell | 16,000 | $32.00 | $512K | Direct | Jul 7, 2017 (2d) |
| Jan 4, 2017 | XLRN | ↓ Sell | 2,000 | $27.46 | $55K | Direct | Jan 6, 2017 (2d) |
| Jul 1, 2016 | XLRN | ↓ Sell | 26,000 | $34.74 | $903K | Direct | Jul 6, 2016 (5d) |
| Apr 7, 2016 | XLRN | ↓ Sell | 26,000 | $32.00 | $832K | Direct | Apr 8, 2016 (1d) |
| Oct 15, 2015 | XLRN | ↓ Sell | 4,800 | $23.30 | $112K | Direct | Oct 16, 2015 (1d) |
| Oct 15, 2015 | XLRN | ↓ Sell | 1,200 | $23.21 | $28K | By GRAT | Oct 16, 2015 (1d) |
| Sep 16, 2015 | XLRN | ↓ Sell | 1,600 | $32.81 | $52K | Direct | Sep 18, 2015 (2d) |
| Sep 16, 2015 | XLRN | ↓ Sell | 400 | $34.96 | $14K | By GRAT | Sep 18, 2015 (2d) |
| Aug 18, 2015 | XLRN | ↓ Sell | 5,600 | $31.07 | $174K | Direct | Aug 19, 2015 (1d) |
| Aug 18, 2015 | XLRN | ↓ Sell | 1,400 | $31.36 | $44K | By GRAT | Aug 19, 2015 (1d) |
| Jul 20, 2015 | XLRN | ↓ Sell | 4,800 | $32.45 | $156K | Direct | Jul 21, 2015 (1d) |
| Jul 20, 2015 | XLRN | ↓ Sell | 1,200 | $32.46 | $39K | By GRAT | Jul 21, 2015 (1d) |
| Jun 18, 2015 | XLRN | ↓ Sell | 5,600 | $31.57 | $177K | Direct | Jun 19, 2015 (1d) |
| Jun 18, 2015 | XLRN | ↓ Sell | 1,400 | $31.43 | $44K | By GRAT | Jun 19, 2015 (1d) |
| May 18, 2015 | XLRN | ↓ Sell | 5,600 | $32.41 | $181K | Direct | May 19, 2015 (1d) |
| May 18, 2015 | XLRN | ↓ Sell | 1,400 | $32.20 | $45K | By GRAT | May 19, 2015 (1d) |
| Apr 20, 2015 | XLRN | ↓ Sell | 4,000 | $33.53 | $134K | Direct | Apr 21, 2015 (1d) |
| Apr 20, 2015 | XLRN | ↓ Sell | 1,000 | $33.50 | $34K | By GRAT | Apr 21, 2015 (1d) |
| Mar 18, 2015 | XLRN | ↓ Sell | 4,800 | $41.18 | $198K | Direct | Mar 20, 2015 (2d) |
| Mar 18, 2015 | XLRN | ↓ Sell | 1,200 | $41.18 | $49K | By GRAT | Mar 20, 2015 (2d) |
| Mar 4, 2015 | XLRN | ↓ Sell | 5,600 | $40.71 | $228K | Direct | Mar 6, 2015 (2d) |
| Mar 4, 2015 | XLRN | ↓ Sell | 1,400 | $40.87 | $57K | By GRAT | Mar 6, 2015 (2d) |
| Jan 20, 2015 | XLRN | ↓ Sell | 5,600 | $41.64 | $233K | Direct | Jan 22, 2015 (2d) |
| Jan 20, 2015 | XLRN | ↓ Sell | 1,400 | $41.63 | $58K | By GRAT | Jan 22, 2015 (2d) |
| Dec 18, 2014 | XLRN | ↓ Sell | 4,000 | $40.15 | $161K | Direct | Dec 19, 2014 (1d) |
| Dec 18, 2014 | XLRN | ↓ Sell | 1,000 | $40.19 | $40K | By GRAT | Dec 19, 2014 (1d) |
| Dec 10, 2014 | XLRN | ↓ Sell | 4,000 | $43.47 | $174K | Direct | Dec 12, 2014 (2d) |
| Dec 10, 2014 | XLRN | ↓ Sell | 1,000 | $43.45 | $43K | By GRAT | Dec 12, 2014 (2d) |
| Nov 18, 2014 | XLRN | ↓ Sell | 4,082 | $33.76 | $138K | Direct | Nov 18, 2014 (0d) |
| Nov 18, 2014 | XLRN | ↓ Sell | 1,000 | $33.75 | $34K | By GRAT | Nov 18, 2014 (0d) |
| Nov 12, 2014 | XLRN | ↓ Sell | 3,918 | $33.12 | $130K | Direct | Nov 14, 2014 (2d) |
| Nov 12, 2014 | XLRN | ↓ Sell | 1,000 | $33.06 | $33K | By GRAT | Nov 14, 2014 (2d) |
| Oct 20, 2014 | XLRN | ↓ Sell | 3,918 | $29.10 | $114K | Direct | Oct 20, 2014 (0d) |
| Oct 20, 2014 | XLRN | ↓ Sell | 1,000 | $29.12 | $29K | By GRAT | Oct 20, 2014 (0d) |
Each row is one filing's trades in one stock, summed. Shares and prices are as filed, before any later stock split.
About Matthew L Sherman's insider trades
Matthew L Sherman is EVP & Chief Medical Officer at Deciphera Pharmaceuticals (DCPH). Since Apr 22, 2014, Matthew has reported no open-market purchases and 74 sales worth $8.6M on SEC Form 4. There have been no open-market trades in the last 12 months.
Their filings also include grants and awards (30 filings), option exercises (29 filings), shares returned to the company (2 filings), other transactions (2 filings). These aren't open-market trades and aren't counted above.
How to read insider trades
Officers, directors and owners of more than 10% of a company must report trades in its stock on SEC Form 4, usually within two business days. Purchases with their own money are the stronger signal: insiders sell for many reasons (taxes, diversification, a house), but buy for one. See every DCPH insider trade, the latest insider trades across the market, or cluster buys, when several insiders buy the same stock within days.